Navigation Links
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies
Date:11/20/2008

SAN MARINO, Calif., Nov. 20 /PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months. Analysis of safety and efficacy data showed no major toxicity, while documenting significant control of tumor growth.

Analysis of efficacy in 42 patients with bone and soft tissue sarcoma showed a dose-response relationship between overall survival and Rexin-G which was highly significant. A confirmatory Phase II study in 17 osteosarcoma patients showed a median overall survival greater than seven months; that is, after failing standard chemotherapies. Two patients are disease-free greater than 6 months after surgical resection of residual tumors and Rexin-G given as both neoadjuvant and adjuvant monotherapy. These studies indicate that (i) intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controls tumor growth and improves survival in a dose-dependent manner in patients with chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about Rexin-G and Epeius Biotechnologies' pipeline of proprietary compounds currently available for clinical development, please visit us at http://www.epeiusbiotech.com .

*(LOGO 72dpi: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

This release was issued on behalf of the above
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
2. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
3. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
4. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
5. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
6. New Insight Into the Controls on a Go-To Enzyme
7. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
8. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
9. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Pennsylvania , 21 de noviembre de 2014 ... de ensayos clínicos externalizados y tecnologías eClinical, ha ... aproximación de ,seguimiento inteligente, para el seguimiento basado ... seguimiento inteligente amplía el concepto del seguimiento basado ... reducción de las visitas de seguimiento o cambio ...
(Date:11/22/2014)... , Nov. 21, 2014 Research and ... Recombinant Protein Drug Industry Report, 2014-2017" report to ... The Chinese recombinant protein drug market has ... rigidity, consumption ability and the like. During 2005-2013, sales ... grew at a CAGR of 19.1%, and it is ...
(Date:11/21/2014)... DIEGO , Nov. 21, 2014  Tandem ... TNDM ), a medical device company and manufacturer ... announced a partnership with Tidepool, a non-profit dedicated ... open source software platform that increases diabetes data ... Tidepool Platform, which is currently under development, to ...
Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3
... 2012 Pharmspective, LLC today announced the release ... - specifically developed to analyze provisions in the ... key pharma customer decision makers who influence product ... research firm providing knowledge management applications to the ...
... March 7, 2012, at 8:30 a.m. Eastern/2:30 p.m. Central ... (NASDAQ and MTA: CTIC) management team will host a ... and year-end achievements and financial results. ... Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time 1-877-941-8609 ...
Cached Medicine Technology:Pharmspective Announces the Release of ClearView™ - a New Health Care Reform Knowledge Management Web Application for the Biopharma Industry 2
(Date:11/22/2014)... 2014 (HealthDay News) -- Those air-blown hand dryers in ... paper towels, a new study suggests. British researchers ... of volunteers in order to simulate poorly washed hands. ... dryers or paper towels to dry their hands. ... amounts of germs around both types of dryers than ...
(Date:11/22/2014)... Amy Norton HealthDay Reporter ... live in nursing homes may commonly deal with aggressive or ... The study of 10 centers in New York state found ... percent of residents were involved in some type of incident ... verbal clash, with someone yelling or cursing at another resident. ...
(Date:11/21/2014)... Lauderdale, FL (PRWEB) November 21, 2014 Body ... services announced that it accepts Spafinder massage gift cards ... and in room hotel massage in all service areas including ... you don't have to go to the spa at all ... Owner and Founder of Body Well. "We may not be ...
(Date:11/21/2014)... THURSDAY, Nov. 20, 2014 (HealthDay News) -- Certain genes ... in up to a fifth of people with type ... has long been pondered by doctors working with diabetic ... have been under the impression that exercise helps decrease ... Dr. Maria Pena, director of the Center for Weight ...
(Date:11/21/2014)... 2014 MLF Biotech, Inc. has developed ... Liv-Pro® Probiotics for Pets helps maintain digestive health and ... pet's intestinal flora after it experiences a period of ... Probiotics for Pets is a proprietary blend of pure ... live active bacteria strains that are safe and effective ...
Breaking Medicine News(10 mins):Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 3Health News:Body Well Mobile Massage Announces Acceptance of Spafinder Gift Cards for In Home Massage, Hotel Massage for Travelers 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 3Health News:MLF Biotech Introduces Liv-Pro Probiotics for Pets 2
... Patients with a certain gene variant drank less ... without the variant while taking the medication naltrexone, ... National Institutes of Health,s 2001-2004 COMBINE (Combined Pharmacotherapies ... About 87 percent of patients with the variant ...
... Fourth Consecutive Quarterly ... Revenue Increase Over Prior Year, SAN DIEGO, Feb. 7 ... today reported financial results for its fourth quarter and,fiscal 2007. Operating ... Vermed which was sold on August 31, 2007., Key Financial ...
... Memory Pharmaceuticals,Corp. (Nasdaq: MEMY ) today ... President & Chief Executive Officer. In support of ... MPM,Capital, Great Point Partners, Oxford Biosciences and Venrock, ... who has served as the,Company,s President & Chief ...
... Finding Health and Mental Health Top the List,of Needs, ... series of tornadoes in decades, many people across the ... Cross continues to help,provide meals, shelter and clean up ... welcome help comes from Red Cross health and mental,health ...
... products for infants , , THURSDAY, Feb. 7 (HealthDay News) ... Canada are calling for a ban on the use ... toddler sippy cups, water bottles and other food and ... polycarbonate bottles [investigated in the study] leached BPA when ...
... What began as a healthy family,recipe for a ... people of all,ages. Triathlete Erin DeMarines, founder of 10-year-old ... 3Bar might have gotten its,start with DeMarines, "friends and ... now available in over 200 retail stores including Publix ...
Cached Medicine News:Health News:Gene variant predicts medication response in patients with alcohol dependence 2Health News:Gene variant predicts medication response in patients with alcohol dependence 3Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 2Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 3Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 4Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 5Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 6Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 7Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 2Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 3Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 4Health News:Tornado-Scarred States Receive American Red Cross Health Services 2Health News:Tornado-Scarred States Receive American Red Cross Health Services 3Health News:Report Shows Dangerous Chemical Can Leach From Baby Bottles 2Health News:Report Shows Dangerous Chemical Can Leach From Baby Bottles 3Health News:New Natural Energy Bar Hits the Road with Dieters & Athletes Alike 2
... The BD Macro-Vue RPR (Rapid ... and Tear-drop Tests are nontreponemal testing ... syphilis described in A Manual of ... in this manual are the most ...
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
Enzyme Immunoassay for the quantitative ( qualitative 0020, on request) determination of IgG Class antibodies to Rubella virus....
Donor Screen & Confirmation Kit...
Medicine Products: